NEW YORK (GenomeWeb) – Myriad Genetics said this week that James Evans will retire as its CFO "in order to attend to family health issues." Evans will continue to perform his duties until a replacement is found. Myriad said it will hire an executive search firm to identify candidates for consideration.

Evans joined Myriad in 1995 as corporate controller and was promoted to VP of finance in July 2005. He became CFO in November 2007. Evans played a leading role in Myriad's acquisitions of Rules-Based Medicine and Crescendo Biosciences.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.